Skip to main content

Table 3 Laboratory outcome measures during randomised treatment phase presented as average [mean (SE)] changes from baseline during weeks 0 – 24 as measured by AUCMB

From: Zidovudine plus lamivudine in Human T-Lymphotropic Virus type-I-associated myelopathy: a randomised trial

  Placebo Active p
HTLV-I proviral loada (log10 copies/105 PBMCs) +0.03 (0.10) +0.05 (0.13) 0.92
Total Lymphocytesb (106/L) +148.2 (58.0) -159.3 (146.7) 0.07
CD3 Lymphocytesb (106/L) +98.4 (63.4) -23.2 (151.3) 0.47
CD3b % +0.2 (2.8) +4.3 (2.6) 0.14
CD4b Lymphocytes (106/L) +32.6 (33.1) +10.4 (98.7) 0.55
CD4b % -1.2 (0.9) +4.7 (1.8) 0.01
CD8b Lymphocytes (106/L) +65.8 (31.3) -38.1 (60.7) 0.15
CD8b % +1.4 (1.2) +1.4 (1.9) 0.99
CD25a % -0.8 (1.8) +0.3 (0.8) 0.58
CD69a % +0.4 (1.3) +1.2 (1.8) 0.73
CD71a% -0.3 (1.0) -0.2 (1.9) 0.97
HLA-DR% -4.85 (4.0) +3.59 (2.4) 0.42
  1. a Data only available on n = 6 in placebo group and n = 7 in active group due to missing baseline data
  2. b Data only available on n = 7 in placebo group and n = 7 in active group due to missing baseline data